Home > Journals > Journal of Radiological Review > Past Issues > Journal of Radiological Review 2022 June;9(2) > Journal of Radiological Review 2022 June;9(2):72-9

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Journal of Radiological Review 2022 June;9(2):72-9

DOI: 10.23736/S2723-9284.22.00193-3

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Criteria for assessing the response to treatments in solid tumor in the era of new oncology: what radiologists should know

Diletta CAVALLERO , Francesco BORRI, Luciana BRUNI, Martina CHIELLINI, Dania CIONI, Emanuele NERI

Academic Radiology, Department of Translational Research, University of Pisa, Pisa, Italy



During the past three decades, different radiological criteria have been developed and used in tumor response evaluation obtained by imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI). Response Evaluation Criteria in Solid Tumors (RECIST 1.1) have become the standard for assessment of response in solid tumors. More recently, modified RECIST (mRECIST) and immune-related RECIST (iRECIST) have been introduced for the evaluation of the hepatocellular carcinoma treatment response and for tumor response to immunotherapy. These criteria represent the gold standard for the evaluation of tumor response, according to tumor histotype and to selected therapy. The knowledge of these standardized criteria is crucial to ensure an objective evaluation, reducing variability, and avoiding misinterpretations that can modify treatment strategy. The purpose of this review article is to describe the characteristics of these criteria by enhancing differences among them.


KEY WORDS: Response evaluation criteria in solid tumors; Diagnostic imaging; Radiology

top of page